SuperworthScribe Therapeutics EPS SCTX
Diluted earnings per share by quarter and over the last twelve months, from 2025.
- Last 12 months, to Jun 30, 2026
- n/m
- a quarter missing
- Latest quarter, Q2 FY26
- −$2.62
Scribe Therapeutics' twelve-month earnings per share can't be added up yet: a quarter of its results is missing from our data.
In its latest quarter, Q2 FY26, it was −$2.62.
Earnings per share over time
Quarter by quarter
| Quarter | Ended | EPS | On a year earlier |
|---|---|---|---|
| Q2 FY26 | −$2.62 | n/a | |
| Q1 FY26 | −$7.05 | n/a | |
| Q2 FY25 | −$4.08 | n/a | |
| Q1 FY25 | −$1.42 | n/a |
Against its peers
Companies in Biotechnology nearest Scribe Therapeutics' size, closest first, today.
| Company | EPS, 12 months | Growth |
|---|---|---|
| SCTXScribe Therapeutics | n/m | |
| PLXProtalix BioTherapeutics | $0.23 | +283% a year |
| MGTXMeiraGTx | $0.71 | |
| VCELVericel | $0.46 | +283% a year |
| ADMAAdma Biologics | $0.70 | −18% a year |
| Peer median | $0.58 |
What the EPS figure tells you
Net income divided by diluted shares. The denominator of PE.
One-off charges and gains swing it. The TTM view smooths a single odd quarter.
More on Scribe Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.